Increasing degradation of Hypoxia-Inducible Factors impairs cancer stem cell proliferation
- 總結
- This technology describes a method for treating ID2 protein-related diseases through increased degradation of Hypoxia-Inducible Factors (HIFs).
- 技術優勢
- Mechanism-backed treatment of ID2 protein-related diseasesApplicable to multiple types of hypoxia-related cancersProvides multiple drug targets for increasing degradation of HIFs, reducing risk of resistance
- 技術應用
- Treatment and prevention of glioblastoma and other cancersTreatment and prevention of other ID2 protein-related diseasesResearch tool for developing additional targeted therapeutics
- 詳細技術說明
- None
- *Abstract
-
None
- *Inquiry
- Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU16166
- *Principal Investigation
-
- *Publications
- Lee S, Frattini V, Bansal M, Castano A, Sherman D, Hutchinson K, Califano A, Liu G, Cordozo T, Iavarone A, Lasorella A. “An ID2-dependent mechanism for VHL inactivation in cancer” Nature. 2016 Jan 14;529(7585):172-177.Tech Ventures Reference:IR CU16166Licensing Contact: Ron Katz
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
